Simultaneous inhibition of IL-6 and IL-8 receptors via Tocilizumab and Reparixin (inhibitor of C-X-C motif chemokine receptor 1) significantly decreased the expression of matrix metalloprotease in mouse MDA-MB-231 breast cancer model models and decreased the incidence of liver and lung metastasis [122]. The gene discussed is IL6; the disease is breast cancer.